These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 9417748

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Incidence, outcome and prediction of early clinical events following percutaneous transluminal coronary angioplasty. A comparison between treatment with reviparin and unfractionated heparin/placebo (results of a substudy of the REDUCE trial).
    Preisack MB, Bonan R, Meisner C, Eschenfelder V, Karsch KR.
    Eur Heart J; 1998 Aug; 19(8):1232-8. PubMed ID: 9740345
    [Abstract] [Full Text] [Related]

  • 4. Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis.
    Gibson CM, Goel M, Cohen DJ, Piana RN, Deckelbaum LI, Harris KE, King SB.
    J Am Coll Cardiol; 1998 Jul; 32(1):28-34. PubMed ID: 9669245
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Prevention of restenosis after coronary balloon angioplasty: rationale and design of the Fluvastatin Angioplasty Restenosis (FLARE) Trial. The FLARE Study Group.
    Foley DP, Bonnier H, Jackson G, Macaya C, Shepherd J, Vrolix M, Serruys PW.
    Am J Cardiol; 1994 May 26; 73(14):50D-61D. PubMed ID: 8198025
    [Abstract] [Full Text] [Related]

  • 7. Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES).
    Jørgensen B, Simonsen S, Endresen K, Forfang K, Vatne K, Hansen J, Webb J, Buller C, Goulet G, Erikssen J, Thaulow E.
    J Am Coll Cardiol; 2000 Mar 01; 35(3):592-9. PubMed ID: 10716459
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial.
    Serruys PW, Klein W, Tijssen JP, Rutsch W, Heyndrickx GR, Emanuelsson H, Ball SG, Decoster O, Schroeder E, Liberman H.
    Circulation; 1993 Oct 01; 88(4 Pt 1):1588-601. PubMed ID: 8403306
    [Abstract] [Full Text] [Related]

  • 10. Experimental and early clinical experience with reviparin-sodium for prevention of restenosis after percutaneous transluminal coronary angioplasty.
    Preisack MB, Karsch KR.
    Blood Coagul Fibrinolysis; 1993 Dec 01; 4 Suppl 1():S55-8; discussion S59-60. PubMed ID: 8180331
    [Abstract] [Full Text] [Related]

  • 11. Low molecular weight heparin in prevention of restenosis after angioplasty. Results of Enoxaparin Restenosis (ERA) Trial.
    Faxon DP, Spiro TE, Minor S, Coté G, Douglas J, Gottlieb R, Califf R, Dorosti K, Topol E, Gordon JB.
    Circulation; 1994 Aug 01; 90(2):908-14. PubMed ID: 8044962
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Local and systemic delivery of low molecular weight heparin following PTCA: acute results and 6-month follow-up of the initial clinical experience with the porous balloon (PILOT-study). Preliminary Investigation of Local Therapy Using Porous PTCA Balloons.
    Oberhoff M, Baumbach A, Hermann T, Diehl C, Maier R, Athanasiadis A, Herdeg C, Bohnet A, Haase KK, Voelker W, Baildon R, Veldhof S, Karsch KR.
    Cathet Cardiovasc Diagn; 1998 Jul 01; 44(3):267-74. PubMed ID: 9676794
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group.
    Faxon DP.
    J Am Coll Cardiol; 1995 Feb 01; 25(2):362-9. PubMed ID: 7829789
    [Abstract] [Full Text] [Related]

  • 18. Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial.
    Gershlick AH, Spriggins D, Davies SW, Syndercombe Court YD, Timmins J, Timmis AD, Rothman MT, Layton C, Balcon R.
    Br Heart J; 1994 Jan 01; 71(1):7-15. PubMed ID: 8297699
    [Abstract] [Full Text] [Related]

  • 19. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
    Lincoff AM, Tcheng JE, Califf RM, Kereiakes DJ, Kelly TA, Timmis GC, Kleiman NS, Booth JE, Balog C, Cabot CF, Anderson KM, Weisman HF, Topol EJ.
    Circulation; 1999 Apr 20; 99(15):1951-8. PubMed ID: 10208997
    [Abstract] [Full Text] [Related]

  • 20. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group.
    Circulation; 1992 Jul 20; 86(1):100-10. PubMed ID: 1535568
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.